Functional near-infrared spectroscopy (fNIRS) measures brain activity optically based on changes in cortical blood flow.

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...

In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

Parth, a seasoned tech writer, wields the keyboard (or pen) with finesse to unravel the intricacies of both Windows and Mac operating systems. He has covered evergreen content on mobile devices and ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject of discussion was Replimune's RP1, a cancer drug being trialed as a ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...